申请人:MannKind Corporation
公开号:EP3150589A1
公开(公告)日:2017-04-05
The present invention relates to compounds which directly inhibit IRE-1α activity, and which are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
本发明涉及直接抑制 IRE-1α 活性的化合物,这些化合物可用于治疗与未折叠蛋白反应相关的疾病,并可用作单药或联合疗法。